Don Morris
0000-0003-2137-9307
Publication & Citation Trends
Most Cited Works
Publications
136 total
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors PDF
Cited by 129
OpenAlex
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma PDF
Cited by 77
OpenAlex
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors PDF
Cited by 76
OpenAlex
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer PDF
Cited by 74
OpenAlex
Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary
Cited by 91
OpenAlex
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
Cited by 108
OpenAlex
Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic PDF
Cited by 96
OpenAlex
Research Topics
Virus-based gene therapy research
(42)
Lung Cancer Treatments and Mutations
(26)
Cancer Research and Treatments
(21)
Viral gastroenteritis research and epidemiology
(20)
Cancer Immunotherapy and Biomarkers
(17)
Frequent Co-Authors
Affiliations
Southern Illinois University Carbondale
Ontario Institute for Cancer Research
University of Maryland, Baltimore
Alberta Health Services
Helmholtz Institute Jena